Scarica l'app Stockscreener
19.77
0.18%
-0.035
Dopo l'orario di chiusura:
19.90
0.13
+0.66%
Precedente Chiudi:
$19.80
Aprire:
$20
Volume 24 ore:
2.44M
Relative Volume:
1.16
Capitalizzazione di mercato:
$6.89B
Reddito:
$3.05B
Utile/perdita netta:
$181.32M
Rapporto P/E:
53.00
EPS:
0.373
Flusso di cassa netto:
$186.11M
1 W Prestazione:
+5.67%
1M Prestazione:
+10.32%
6M Prestazione:
+61.26%
1 anno Prestazione:
+105.94%
Intervallo 1D:
$19.33
$20.00
Intervallo di 1 settimana:
$18.73
$21.18
Portata 52W:
$9.56
$21.18
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, TEVA, HLN, ZTS, VTRS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
19.77 | 6.89B | 3.05B | 181.32M | 186.11M | 0.373 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-17 | Iniziato | UBS | Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
| 2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-27 | Iniziato | Goldman | Sell |
| 2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
| 2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Downgrade | SunTrust | Buy → Hold |
| 2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Iniziato | Morgan Stanley | Overweight |
| 2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Amneal Pharmaceuticals' Biosimilars, Specialty Growth Reshape Earnings Profile, Oppenheimer Says - marketscreener.com
Oppenheimer initiates Amneal Pharmaceuticals stock with outperform rating By Investing.com - Investing.com Nigeria
Oppenheimer initiates Amneal Pharmaceuticals stock with outperform rating - Investing.com
Oppenheimer Initiates Amneal Pharmaceuticals at Outperform With $27 Price Target - Yahoo Finance
Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September By Investing.com - Investing.com Canada
Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September - Investing.com India
Amneal Pharmaceuticals, Inc. (AMRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amneal Pharmaceuticals, Inc. (AMRX) stock price, news, quote and history - Yahoo Finance UK
Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.com - Investing.com Nigeria
Amneal: Even My Bull Case Barely Justifies $20/Share (NASDAQ:AMRX) - Seeking Alpha
Amneal Pharmaceuticals Inc (AMRX) Shares Surge 7.8% -- What GF S - GuruFocus
Amneal Pharmaceuticals Director Kevin J. Buchi Transfers 20,445 Shares to Trust - kalkinemedia.com
Why Is Amneal (AMRX) Stock Rocketing Higher Today - Yahoo Finance
Amneal (NASDAQ: AMRX) director gifts 20,445 shares to trust he oversees - Stock Titan
Amneal Pharmaceuticals Jumps 6.4% After Barclays Maintains Overweight - AlphaStreet
Update: Amneal Pharmaceuticals Shares Rise After FDA Approval for Lanreotide Injection - Yahoo Finance
Amneal Pharmaceuticals stock hits 52-week high at 19.32 USD - Investing.com
Amneal Launches Its Generic Lanreotide Immediately While the Brand Still Posts Nearly a Billion in US Sales - Medical Daily
Amneal Pharmaceuticals stock gains after FDA approval for lanreotide injection - AD HOC NEWS
Amneal receives FDA approval for generic lanreotide injection By Investing.com - Investing.com Nigeria
AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod - Yahoo Finance
Stocks to Watch : Paramount Skydance, Warner Bros. Discovery, Accenture, Amneal Pharmaceuticals - marketscreener.com
Amneal Pharmaceuticals Secures FDA Approval for Lanreotide Injection - Yahoo Finance
Amneal receives FDA approval for generic lanreotide injection - Investing.com
An injection for three conditions launches immediately after FDA approval - Stock Titan
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains? - Eastern Progress
Amneal Pharmaceuticals Inc. (AMRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Amneal Pharmaceuticals Inc (AMRX) Stock Down 3.3% but Still Over - GuruFocus
Insider Unloading: KEVIN BUCHI Sells Options, Realizes $54K - Benzinga
Kentucky Gov. Andy Beshear visits Amneal's Glasgow facility - goSkagit
Amneal Pharmaceuticals, Inc.Class A Common Stock (NQ: AMRX - The Chronicle-Journal
Leerink Partners Initiates Coverage on Amneal Pharmaceuticals With Outperform, $23 Price Target - marketscreener.com
Does Amneal’s New US$523 Million Shelf Registration Reframe Its Capital Allocation Story for AMRX? - simplywall.st
Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)? - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Stock Sees Modest Fair Value Lift On Launch Optimism - Yahoo Finance
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns - Reuters
Amneal Pharmaceuticals files prospectus for sale of up to 28.9 million shares - scanx.trade
Amneal Pharmaceuticals (AMRX) Following Its Biosimilars Push And The Fair Value Debate - simplywall.st
Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX) - Yahoo Finance
Amneal Pharmaceuticals Says US FDA Approves Romidepsin Injection Solution - Moomoo
J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Amneal builds end-to-end biosimilars capacity in the U.S. - Chain Drug Review
Amneal Pharmaceuticals (AMRX) Stock Looks Fairly Valued But Earnings Still Look Rich - sahmcapital.com
Amneal (AMRX) Results Review: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction: The Share Price Adds 1.87% in the Current UpdateProfit Warning Alert - Vinanet
Amneal (AMRX) Earnings Report: EPS Beats Its Estimate in Latest Trading; The Market Price Declines 1.25% in the Latest SessionDiluted EPS Report - vinanet.vn
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm - Business Wire
Zacks.com featured highlights include CareDx, Healthcare Services, Forum Energy Tech, Amneal Pharma and Caterpillar - Yahoo Finance
Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance - Sahm
Is Amneal Pharmaceuticals (AMRX) Fairly Valued After A 3.5x Return? - Yahoo Finance
AMRX Q2 2026 Earnings: Strong EPS Beat Drives 5.1% RallyEarnings Revision Upgrade - vinanet.vn
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):